0576 Disability and impact profile in multiple sclerosis patients treated with high-dose interferon beta-1a

2005 ◽  
Vol 238 ◽  
pp. S245
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
High Dose ◽  
Multiple Sclerosis Patients ◽  
High Dose Interferon

Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

2010 ◽  
Vol 16 (4) ◽  
pp. 450-454 ◽  
Author(s):  
Roberta Lanzillo ◽  
Giuseppe Orefice ◽  
Mario Quarantelli ◽  
Carlo Rinaldi ◽  
Anna Prinster ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Low Dose ◽  
Interferon Beta ◽  
High Dose ◽  
Contrast Enhanced ◽  
Relapsing Remitting ◽  
Group A ◽  
Group B ◽  
Multiple Sclerosis Patients ◽  
High Dose Interferon

A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action. Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis. Our objectives were to determine safety, tolerability and efficacy of low-dose atorvastatin plus high-dose interferon beta-1a in multiple sclerosis patients responding poorly to interferon beta-1a alone. Relapsing—remitting multiple sclerosis patients, aged 18—50 years, with contrast-enhanced lesions or relapses while on therapy with interferon beta-1a 44 µg (three times weekly) for 12 months, were randomized to combination therapy (interferon + atorvastatin 20 mg per day; group A) or interferon alone (group B) for 24 months. Patients underwent blood analysis and clinical assessment with the Expanded Disability Status Scale every 3 months, and brain gadolinium-enhanced magnetic resonance imaging at screening, and 12 and 24 months thereafter. Primary outcome measure was contrast-enhanced lesion number. Secondary outcome measures were number of relapses, EDSS variation and safety laboratory data. Forty-five patients were randomized to group A ( n = 21) or B ( n = 24). At 24 months, group A had significantly fewer contrast-enhanced lesions versus baseline ( p = 0.007) and significantly fewer relapses versus the two pre-randomization years ( p < 0.001). At survival analysis, the risk for a 1-point EDSS increase was slightly higher in group B than in group A (p = 0.053). Low-dose atorvastatin may be beneficial, as add-on therapy, in poor responders to high-dose interferon beta-1a alone.

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

2000 ◽  
Vol 178 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Luca Durelli ◽  
Alessandra Oggero ◽  
Elisabetta Verdun ◽  
Gianluca Isoardo ◽  
Alessandra Ricci ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
High Dose ◽  
Multiple Sclerosis Patients ◽  
High Dose Interferon

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β

2014 ◽  
Vol 20 (13) ◽  
pp. 1783-1787 ◽  
Author(s):  
Catherine Larochelle ◽  
François Grand’maison ◽  
Gilles P Bernier ◽  
Mathieu Latour ◽  
Jean-François Cailhier ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Hemolytic Uremic Syndrome ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Interferon Beta ◽  
High Dose ◽  
Thrombocytopenic Purpura ◽  
Relapsing Remitting ◽  
Uremic Syndrome ◽  
Relapsing Remitting Multiple Sclerosis ◽  
High Dose Interferon

Three women aged 34–47 years old, on high dose interferon beta-1a for relapsing–remitting multiple sclerosis, were hospitalized between 2009–2012 for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Patients sought medical attention for neurological symptoms including cephalalgia, blurred vision, confusion, focal deficits and seizures. All patients presented thrombocytopenia, hemolytic anemia and arterial hypertension. Despite plasma exchanges, corticosteroids and anti-CD20 treatments, all patients progressed towards severe renal insufficiency and one patient died of hemorrhagic shock. In this report we identify a rare but morbid complication of interferon beta-1a treatment associated with female gender, Caucasian background and low body mass index.

scholarly journals Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial

2017 ◽  
Vol 3 (8) ◽  
pp. 1-8 ◽  
Author(s):  
Masoud Etemadifar ◽  
◽  
Pedram Moeini ◽  
Seyed-Masoud Nabavi ◽  
◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Interferon Beta ◽  
High Dose ◽  
High Dose Interferon
Sign in / Sign up

Export Citation Format

Share Document